Press Releases
Dr. Adam Darwich is Appointed Certara Lecturer in Precision Dosing at The University of Manchester, England
PRINCETON, NJ - May 12, 2016 - Certara®, the global biosimulation technology-enabled drug development company, today announced that Adam Darwich, PhD, has been appointed Certara Lecturer in Precision Dosing at the Manchester Pharmacy School at The University of Manchester in England. Certara has endowed this lectureship, which is part of the Universitys precision medicine initiative. It is intended to advance teaching and research of modeling and simulation for individual dose optimization, ultimately at the point of care.
While biosimulation has been widely accepted and adopted by biopharmaceutical companies and global regulatory agencies, its implementation in clinical care has been modest to date, said Certara Chief Executive Officer Edmundo Muniz, MD, PhD. We are delighted to have a researcher of Adams caliber helping to advance this field and teaching these important modeling techniques to the next generation of scientists in drug development and patient care. This lectureship is just one way in which Certara is working to make precision dosing a reality for everyone.
Later this month, The University of Manchester will host the Health Care Summit on Model-based Precision Dosing, for which Certara is the sole sponsor. During the Summit, world key opinion leaders will share their ideas and experiences, and discuss the path forward for implementing biosimulation in individual patient care. Areas of focus include work done across specific population cohorts, including oncology patients, HIV patients, obese subjects, pregnant women, and pediatric patients.
Professor Amin Rostami, who is the chair of systems pharmacology at The University of Manchester and chief scientific officer at Certara, said, This event provides a unique opportunity for many renowned thought leaders from across the world, whether they are clinicians or scientists from academia or healthcare sectors, to debate various activities which will facilitate the use of modeling and simulation for precision dosing. This event would not have happened if it was not for the forward thinking of Certara which sponsored it.
Dr. Darwich, who will co-chair the Summit together with Professor Rostami, has extensive PK modeling experience, which includes PBPK modeling of drug-drug interactions (DDIs), interspecies extrapolation, and extrapolation to special populations, biopharmaceutics and clinical study design. His previous research focused on PBPK modeling and simulation of oral drug bioavailability in bariatric surgery patients and mechanism-based inhibition of gut wall metabolism.
As part of his new role, Dr. Darwich is already partnering with healthcare professionals and other collaborators on a number of projects, including modeling biologics, DDIs and special populations.
Underscoring its prominence in this area, Manchester is one of six initial regional centers of excellence for The Precision Medicine Catapult, the UKs innovation center for precision medicine.
About Certara
Certara is a global biosimulation and regulatory writing company, committed to optimizing drug development decisions. Its clients include hundreds of international biopharmaceutical companies, leading academic institutions, and key regulatory agencies. Certaras solutions, which span drug discovery through patient care, increase the probability of regulatory and commercial success by using the most scientifically-advanced modeling and simulation technologies and regulatory strategies. For more information, visit www.certara.com.
